Search hospitals

>

Pennsylvania

>

Philadelphia

University of Pennsylvania

Claim this profile

Philadelphia, Pennsylvania 19104

Global Leader in HIV Infection

Global Leader in Human Immunodeficiency Virus Infection

Conducts research for Heart Failure

Conducts research for Cancer

Conducts research for Lung Cancer

1932 reported clinical trials

267 medical researchers

Photo of University of Pennsylvania in PhiladelphiaPhoto of University of Pennsylvania in PhiladelphiaPhoto of University of Pennsylvania in Philadelphia

Summary

University of Pennsylvania is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Heart Failure, Cancer, Lung Cancer and other specialties. University of Pennsylvania is involved with conducting 1,932 clinical trials across 2,338 conditions. There are 267 research doctors associated with this hospital, such as Nimesh Desai, MD, Arati Desai, MD, Angela DeMichele, MD, and Wilson Szeto, MD.

Top PIs

Clinical Trials running at University of Pennsylvania

Heart Failure

Cancer

Stroke

Age-Related Macular Degeneration

Breast Cancer

Pancreatic Cancer

Chronic Lymphocytic Leukemia

Atrial Fibrillation

Cystic Fibrosis

Carcinoid Tumor

Image of trial facility.

Catheter Ablation + HF Therapies

for Heart Failure and Atrial Fibrillation

Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control has not been studied in this population. Catheter ablation and antiarrhythmic drugs are rhythm control therapies that have been used for treatment of AF without HF or HF with reduced systolic function but have not been widely applied in HFpEF. No controlled comparative evaluation has been performed in HFpEF. The introduction of wireless pulmonary artery hemodynamic monitoring has permitted optimization of HF therapy in patients with chronic HF with reduced and preserved EF. Reduction in HF hospitalizations has been observed in post hoc analyses of HFpEF patients but has not been systematically applied in AF patients with HFpEF. In this study, we propose to study both rhythm control and optimized HF therapeutic approaches in an AF with HFpEF study population in a pilot study using a sequential two phase randomized controlled clinical trial design.

Recruiting

3 awards

Phase 4

13 criteria

Image of trial facility.

Ziltivekimab

for Heart Failure and Inflammation

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

Recruiting

1 award

Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Pennsylvania?

Where is University of Pennsylvania located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Pennsylvania accept?

What awards or recognition has University of Pennsylvania received?